Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Chikungunya Virus Vaccine Shows Promise in Early Clinical Trial

Will Boggs, MD  |  

The research did not have commercial funding, but patents for the vaccine have been licensed by the National Institutes of Health to Emergent BioSolutions. Two of Dr. Chen’s coauthors were employees of Emergent BioSolutions.

References

ADVERTISEMENT
SCROLL TO CONTINUE
  1. Chen GL, Coates EE, Plummer SH, et al. Effect of a chikungunya virus-like particle vaccine on safety and tolerability outcomes: A randomized clinical trial. JAMA. 2020 Apr 14;323(14):1369–1377.
  2. Stapleford KA, Mulligan MJ. A new vaccine for Chikungunya virus. JAMA. 2020 Apr 14;323(14):1351–1352.

Related Articles

    Mosquito-Borne Chikungunya Virus Can Cause Long-Term Arthritis

    Chikungunya is among a group of 16 diseases transmitted through mosquito, tick or flea bites that is of increasing public health concern in the U.S. Although few rheumatologists are likely to diagnose patients with the acute phase of the disease, they may encounter a handful of patients each year who complain of persistent, and often…

    Experimental Drug Combination Curbs Chikungunya Arthritis in Mice

    Doctors have had few options to treat the chronic rheumatoid arthritis-like symptoms associated with chikungunya virus infections beyond over-the-counter pain relievers. A recent study in Science Translational Medicine has spurred new optimism by finding that a combination therapy—the anti-rheumatic drug abatacept paired with a chikungunya-neutralizing monoclonal antibody—abolished acute symptoms in infected mice.1 The strategy must…